Contract research organisation (CRO) Medicilon USA Corp (Medicilon) announced on Thursday that it has started operations at its second R&D centre in Massachusetts, USA.

The facility is to focus on research of animal models for PK/PD and toxicology studies.

The company says that the new laboratory supplements the company's diverse R&D platforms with cutting-edge resources and uses advanced instrumentation and animal laboratories.

Dr Qingcong Lin, Medicilon USA president, said, 'Boston, with its top-tier pharmaceutical innovation and technological resources, is a strategic choice for Medicilon to enhance its presence. Medicilon will leverage local advantages to stimulate internal potential, strengthen technological capabilities, and explore new fields in drug development through innovation and collaboration.'